[1. G. Levy, What are narrow therapeutic index drugs? Clin. Pharmacol. Ther. 63 (1998) 501-505; https://doi.org/10.1016/S0009-9236(98)90100-X10.1016/S0009-9236(98)90100-X]Search in Google Scholar
[2. L. X. Yu, Quality and bioequivalence standards for narrow therapeutic index drugs, GPhA 2011 Fall Technical Workshop, Bethesda, Maryland, USA, Oct 1-2, 2012; http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM292676.pdf; last access date March 19, 2017.]Search in Google Scholar
[3. US Food&Drug Administration, CFR - Code of Federal Regulations, Title 21 - Food and Drugs, Chapter I - Food and Drug Administration, Subchapter D - Drugs for Human Use, Part 320 - Bioavailability and Bioequivalence Requirements, Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products, Sec. 320.33 - Criteria and Evidence to Assess Actual or Potential Problems, Department of Health and Human Services, Silver Spring (MD) 2017, Vol. 5; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33; last acces date March 19, 2017.]Search in Google Scholar
[4. J. Tamargo, J. L. Heuzey and P. Mabo, Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide, Eur. J. Clin. Pharmacol. 71 (2015) 549-567; https://doi.org/10.1007/s00228-015-1832-010.1007/s00228-015-1832-0441268825870032]Search in Google Scholar
[5. G. M. Currie, J. M. Wheat and H. Kiat, Pharmacokinetic considerations for digoxin in older people, Open Cardiovasc. Med. J. 5 (2011) 130-135; https://doi.org/10.2174/187419240110501013010.2174/1874192401105010130313494621769303]Search in Google Scholar
[6. A. Yacobi, E. Masson, D. Moros, D. Ganes, C. Lapointe, Z. Abolfathi, M. LeBel, Y. Golander, D. Doepner, T. Blumberg, Y. Cohen and B. Levitt, Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin, J. Clin. Pharmacol. 40 (2000) 826-835; https://doi.org/10.1177/0091270002200955810.1177/0091270002200955810934666]Search in Google Scholar
[7. M. Bialer, R. H. Levy and E. Perucca, Does carbamazepine have a narrow therapeutic plasma concentration range? Ther. Drug Monit. 20 (1998) 56-59; https://doi.org/10.1097/00007691-199802000-0001010.1097/00007691-199802000-000109485555]Search in Google Scholar
[8. J. Pesce, M. Rashkin and U. Kotagal, Standards of laboratory practice: theophylline and caffeine monitoring, Clin. Chem. 44 (1998) 1124-1128.]Search in Google Scholar
[9. J. W. Shin, K. Chu, K. H. Jung, S. T. Lee, J. Moon and S. K. Lee, Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations, Int. J. Clin. Pharmacol. Ther. 52 (2014) 1017-1022; https://doi.org/10.5414/CP20215310.5414/CP20215325295717]Search in Google Scholar
[10. M. S. Paveliu, S. Bengea and F. S. Paveliu, Generic substitution issues: brand-generic substitution, generic-generic substitution, and generic substitution of narrow therapeutic index (NTI)/critical dose drugs, Maedica (Bucharest) 6 (2011) 52-58.]Search in Google Scholar
[11. Commonwealth of Pennsylvania, Generic Drug Equivalency/Substitution Laws and Regulations, Philadelphia (PA) April 1, 2017; https://apps.health.pa.gov/pdf/ddc/generic34.pdf; last access date June 21, 2017.]Search in Google Scholar
[12. W. C. Tom and K. Dotson, State regulations on generic substitution, Pharm. Lett. 22 (2006) Document# 220901.]Search in Google Scholar
[13. M. L. Chen, V. P. Shah, D. J. Crommelin, L. Shargel, D. Bashaw, M. Bhatti, H. Blume, J. Dressman, M. Ducharme, P. Fackler, T. Hyslop, L. Lutter, J. Morais, E. Ormsby, S. Thomas, Y. C. Tsang, R. Velagapudi and L. X. Yu, Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report, AAPS J. 13 (2011) 556-564; https://doi.org/10.1208/s12248-011-9294-510.1208/s12248-011-9294-5323185521845486]Search in Google Scholar
[14. FDA@Drugs, Coumadin Label (2016); http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf; last access date March 19, 2017.]Search in Google Scholar
[15. A. R. Sheth, W. W. Brennessel, V. G. Young, F. X. Muller and D. J. Grant, Solid-state properties of warfarin sodium 2-propanol solvate, J. Pharm. Sci. 93 (2004) 2669-2680; https://doi.org/10.1002/jps.2016410.1002/jps.2016415389677]Search in Google Scholar
[16. United States Pharmacopeia 39 - National Formulary 34, USP Convention, Rockville (MD) 2016.]Search in Google Scholar
[17. Z. Rahman, M. Korang-Yeboah, A. Siddiqui, A. Mohammad and M. A. Khan, Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product, Int. J. Pharm. 495 (2015) 19-30; https://doi.org/10.1016/j.ijpharm.2015.08.06510.1016/j.ijpharm.2015.08.06526319638]Search in Google Scholar
[18. A. Nguyenpho, A. B. Ciavarella, A. Siddiqui, Z. Rahman, S. Akhtar, R. Hunt, M. Korang-Yeboah and M. A. Khan, Evaluation of in-use stability of anticoagulant drug products: warfarin sodium, J. Pharm. Sci. 104 (2015) 4232-4240; https://doi.org/10.1002/jps.2465710.1002/jps.2465726501849]Search in Google Scholar
[19. M. Korang-Yeboah, S. Akhtar, A. Siddiqui, Z. Rahman and M. A. Khan, Application of NIR chemometric methods for quantification of the crystalline fraction of warfarin sodium in drug products, Drug Dev. Ind. Pharm. 13 (2015) 1-11; https://doi.org/10.3109/03639045.2015.105881710.3109/03639045.2015.1058817]Search in Google Scholar
[20. A. Siddiqui, Z. Rahman, M. Korang-Yeboah and M. A. Khan, Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products, Int. J. Pharm. 493 (2015) 1-6; https://doi.org/10.1016/j.ijpharm.2015.07.05110.1016/j.ijpharm.2015.07.051]Search in Google Scholar
[21. Z. Rahman, A. A. Mohammad, S. Akhtar, A. Siddiqui, M. Korang-Yeboah and M. A. Khan, Chemometric model development and comparison of Raman and (13)C solid-state nuclear magnetic resonance-chemometric methods for quantification of crystalline/amorphous warfarin sodium fraction in the formulations, J. Pharm. Sci. 104 (2015) 2550-2558; https://doi.org/10.1002/jps.2452410.1002/jps.24524]Search in Google Scholar
[22. C. F. Poole and S. K. Poole, Chromatography Today, Elsevier Science, Amsterdam 1991, pp. 133.]Search in Google Scholar
[23. C. A. Cramers, J. A. Rijiks and P. Bocek, Packed versus capillary columns in gas chromatography, Clin. Chim. Acta 34 (1971) 159-167; https://doi.org/10.1016/0009-8981(71)90169-010.1016/0009-8981(71)90169-0]Search in Google Scholar
[24. E. Sarban, S. Socaci, M. Tofana, M. Simona and M. Bojita, Advantages of „headspace” technique for GC/MS analysis of essential oils, Farmacia 60 (2012) 249-256.]Search in Google Scholar
[25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, ICH, Geneva, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access March 19, 2017.]Search in Google Scholar
[26. A. Gupta, A. B. Ciavarella, V. A. Sayeed, M. A. Khan and P. J. Faustino, Development and application of validated HPLC method for the analysis of dissolution samples of gabapentin drug products, J. Pharm. Biomed. Anal. 46 (2008) 181-186; https://doi.org/org/10.1016/j.jpba.2007.08.02310.1016/j.jpba.2007.08.02317935923]Search in Google Scholar
[27. D. Awotwe-Otoo, C. Agarabi, P. J. Faustino, M. J. Habib, S. Lee, M. A. Khan, and R. B. Shah, Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate, J. Pharm. Biomed. Anal. 62 (2012) 61-67; https://doi.org/10.1016/j.jpba.2012.01.00210.1016/j.jpba.2012.01.00222316620]Search in Google Scholar
[28. FDA, CDER, Reviewer Guidance - Validation of Chromatographic Methods, Rockville (MD) 1994; https://www.fda.gov/downloads/Drugs/Guidances/UCM134409.pdf; last access date March 19, 2017.]Search in Google Scholar